| Aliskiren combined with losartan in type 2 diabetes and nephropathy HH Parving, F Persson, JB Lewis, EJ Lewis, NK Hollenberg New England Journal of Medicine 358 (23), 2433-2446, 2008 | 1534 | 2008 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1450 | 2012 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 339 | 2017 |
| Urinary proteomics for early diagnosis in diabetic nephropathy P Zürbig, G Jerums, P Hovind, RJ MacIsaac, H Mischak, SE Nielsen, ... Diabetes 61 (12), 3304-3313, 2012 | 277 | 2012 |
| Diagnosis of diabetic kidney disease: state of the art and future perspective F Persson, P Rossing Kidney international supplements 8 (1), 2-7, 2018 | 230 | 2018 |
| Diagnosis and prediction of CKD progression by assessment of urinary peptides JP Schanstra, P Zürbig, A Alkhalaf, A Argiles, SJL Bakker, J Beige, ... Journal of the American Society of Nephrology 26 (8), 1999-2010, 2015 | 215 | 2015 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 195 | 2018 |
| Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes F Persson, P Rossing, KJ Schjoedt, T Juhl, L Tarnow, CDA Stehouwer, ... Kidney international 73 (12), 1419-1425, 2008 | 183 | 2008 |
| Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria F Persson, P Rossing, H Reinhard, T Juhl, CDA Stehouwer, C Schalkwijk, ... Diabetes care 32 (10), 1873-1879, 2009 | 181 | 2009 |
| Implementation of proteomic biomarkers: making it work H Mischak, JPA Ioannidis, A Argiles, TK Attwood, E Bongcam‐Rudloff, ... European journal of clinical investigation 42 (9), 1027-1036, 2012 | 162 | 2012 |
| YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria CN Rathcke, F Persson, L Tarnow, P Rossing, H Vestergaard Diabetes care 32 (2), 323-328, 2009 | 159 | 2009 |
| A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus SS Roscioni, D De Zeeuw, ME Hellemons, H Mischak, P Zürbig, ... Diabetologia 56, 259-267, 2013 | 154 | 2013 |
| Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function S Petrykiv, CD Sjöström, PJ Greasley, J Xu, F Persson, HJL Heerspink Clinical Journal of the American Society of Nephrology 12 (5), 751-759, 2017 | 135 | 2017 |
| Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational … N Tofte, M Lindhardt, K Adamova, SJL Bakker, J Beige, JWJ Beulens, ... The lancet Diabetes & endocrinology 8 (4), 301-312, 2020 | 129 | 2020 |
| Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY … M Lindhardt, F Persson, G Currie, C Pontillo, J Beige, C Delles, ... BMJ open 6 (3), e010310, 2016 | 125 | 2016 |
| Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy J Siwy, JP Schanstra, A Argiles, SJL Bakker, J Beige, P Boucek, K Brand, ... Nephrology Dialysis Transplantation 29 (8), 1563-1570, 2014 | 122 | 2014 |
| Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy F Persson, P Rossing, P Hovind, CDA Stehouwer, C Schalkwijk, L Tarnow, ... Diabetes 55 (12), 3550-3555, 2006 | 121 | 2006 |
| Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes S Theilade, M Lajer, F Persson, C Joergensen, P Rossing Diabetes care 36 (3), 715-721, 2013 | 116 | 2013 |
| Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study F Persson, P Rossing, P Hovind, CDA Stehouwer, CG Schalkwijk, ... Scandinavian journal of clinical and laboratory investigation 68 (8), 731-738, 2008 | 107 | 2008 |
| Microalbuminuria: a parameter that has changed diabetes care HH Parving, F Persson, P Rossing Diabetes research and clinical practice 107 (1), 1-8, 2015 | 102 | 2015 |
Peter RossingSteno Diabetes CenterBestätigte E-Mail-Adresse bei dadlnet.dk
